Does Wegovy slow down digestion — and what does that mean for you?

What the evidence says about semaglutide and gastric emptying

The STEP 1 trial (published in the New England Journal of Medicine) established semaglutide 2.4mg as producing around 15% average weight loss over 68 weeks in adults with obesity. But the mechanism underpinning that result is worth understanding, because it is not purely appetite suppression at the brain level. Semaglutide activates GLP-1 receptors in the gut wall as well as the central nervous system, and one consequence of that peripheral action is a measurable slowing of gastric emptying, something our page on how Wegovy slows digestion explains in full detail. Food sits in the stomach for longer before passing into the small intestine.

This is not unique to Wegovy; it applies to the whole GLP-1 drug class. What the trial data show is that the effect is most significant during the early dose-escalation phase and tends to become less acute once a maintenance dose is established and the body has adapted. Some people notice it primarily as a reduced appetite; others experience it more directly as bloating, reflux, or a sense that even a modest meal feels like a lot. Both are the same mechanism at work.

The practical upshot: eating more slowly, chewing thoroughly, and keeping portions moderate tends to sit better with most people on Wegovy, and if you find your Wegovy weight loss is slowing down, these same digestive changes are often part of the picture worth reviewing. Those details matter more than they would off treatment.

How slowed digestion connects to Wegovy's side effect profile

Gastric slowing is the thread that runs through most of Wegovy's common gastrointestinal side effects. Nausea is the most frequently reported, particularly after starting or after a dose increase. Reflux, indigestion, and burping are also common — food and stomach acid have more time to press against the lower oesophageal sphincter when emptying is delayed. If you want a fuller picture of how Wegovy's digestive effects present and settle over time, our page on Wegovy and indigestion goes into practical detail.

These effects are typically at their worst in the first one to two weeks at any new dose level, then ease. That is why Wegovy's titration schedule (starting at 0.25mg and stepping up gradually) exists: it gives the digestive system time to adapt before the therapeutic doses are reached. Stopping treatment abruptly or self-escalating faster than prescribed tends to amplify these symptoms considerably. Any persistent, severe, or worsening abdominal symptoms should be assessed promptly, particularly severe stomach pain that radiates to the back, which warrants urgent medical attention and may indicate pancreatitis, a recognised but infrequent risk with GLP-1 medicines flagged in a 2026 MHRA Drug Safety Update.

Suspected side effects can be reported using the Yellow Card scheme.

Does semaglutide slow digestion permanently, or does it reverse?

The slowdown is pharmacological, not structural. It persists as long as semaglutide is active in the body and does not permanently alter the digestive tract. When treatment stops, gastric emptying returns to its previous rate over the washout period, which for semaglutide, given its long half-life of around a week, means effects fade gradually over several weeks rather than overnight.

There is an interesting nuance here: some research suggests gastric emptying slows most dramatically at lower semaglutide concentrations and the effect partially moderates at steady-state higher concentrations. This is one reason some people find nausea particularly bad at the start of each dose increase and then find it subsides again. The question of whether Wegovy slows down metabolism is a separate topic, but the two are connected, as appetite signals adapt alongside gastric effects.

For anyone curious whether their digestion affects how well semaglutide is absorbed from the gut, the mechanism is slightly different for the oral Wegovy tablet versus the injection; the semaglutide absorption page covers this in more detail. The injection bypasses the digestive tract entirely for its own absorption, so altered gastric emptying does not affect how much semaglutide reaches the bloodstream, though it does affect how food and other oral medicines move through.

What this means practically, including for other medicines

Slowed gastric emptying has one clinically important implication beyond side effects: it can alter the absorption timing of oral medicines taken alongside Wegovy. The most discussed example is the combined oral contraceptive pill. Because semaglutide slows digestion, the pill may be absorbed more slowly or less reliably during the early weeks of treatment, the NHS England guidance on weight-management injections advises discussing contraception with your prescriber before starting. An additional barrier method is commonly recommended during the dose-escalation phase.

More broadly, people managing other conditions with time-sensitive oral medicines (for instance, levothyroxine for an underactive thyroid, which is usually taken on an empty stomach first thing in the morning, much like the Wegovy tablet itself) should flag this with their prescriber. The interactions are manageable; they are not a reason to avoid treatment, but they do need to be factored in from the outset rather than figured out after the fact. A question our prescribers hear fairly regularly is whether digestive enzyme supplements help ease the adjustment period, there is a dedicated look at digestive enzymes and Wegovy if that is something you are weighing up.

If you are thinking about whether Wegovy is the right treatment for your situation, the free consultation with our clinical team is the place to explore that, your answers are reviewed the same day by a real prescriber, not automated.